Portable Low-Volume Therapy for Severe Blood Loss
Annual rept. 9 May 2011-8 May 2012
MINNESOTA UNIV DULUTH
Pagination or Media Count:
The primary goal of the research described in the initial Statement of Work is to advance the development of BHBM so that it is ready for deployment as a portable fast-acting therapy for blood loss. To facilitate deployment, studies will optimize the formulation by increasing our understanding of its mechanism of action in animal models under conditions of 60 blood loss. The low concentration end of the full-factorial design described in Specific Aim 1 was explored in rats. Survival curves were compared after 24 hours using a Wilcoxon test. There was a significant difference p less than 0.05 in survival treatment no. 1 0.4 M D-BHB, 43 mM melatonin, 10 DMSO showed 33 survival treatment no 2 2 M D-BHB, 4.3 mM melatonin, 10 DMSO, 71 survival. From our data and that of Klein et al, it appears that the animal requires a high concentration of D-BHB in order to overcome the negative effects of hemorrhagic shock.
- Medicine and Medical Research
- Medical Facilities, Equipment and Supplies